Rethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/0 Comments/in Expert Insights, Observational, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Scientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types October 8, 2025
- New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy October 7, 2025
- Phase 2 Trial Compares Cabazitaxel and ARPIs in Poor-Prognosis mCRPC After Docetaxel October 7, 2025
- LUNAR Trial Shows Combination Therapy Doubles Progression-Free Survival in Recurrent Prostate Cancer October 7, 2025